Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$1.5M
56.84K shares · 0.0% of portfolio
Envista Holdings Corp
Envista Holdings Corp (NVST) is listed on NYSE and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Brea, United States and has 12,000 employees. The company is worth $3.85B and trades at 41.3x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $2.72B in fiscal 2025, up 8.3% from the year before. Net income was $47M. The share price is 21.2% below its 52-week high of $30.42. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $106.02M. In that quarter, 4 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -41.0% over 5Y.
today you would have $585.68▼ -41.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $21.71 | $19.29 | $24.06 | $33.67 | $45.06 | $33.73 | $29.64 | |
| P/E | 24.6x | 77.5x | — | — | 24.6x | 23.5x | 168.6x | 18.5x |
| P/S | 2.1x | 1.3x | 1.3x | 1.6x | 2.1x | 2.9x | 2.8x | 2.1x |
| P/B |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 7.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 24.6 across this company’s own years on record.
Cash flow growing 7.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NHCNational Healthcare Corp | $243.07 | 27.3x | 3.4x | 1.10% | 13.27% | $3.81B |
| ADPTAdaptive Biotechnologies Corp | $24.41 | — | 27.2x | 0.00% | -38.76% | $3.9B |
| IRTCiRhythm Holdings, Inc. | $119.64 | — | 21.2x | 0.00% | -9.63% | $3.94B |
| VCYTVeracyte Inc | $46.04 |
| 1.3x |
| 1.1x |
| 1.1x |
| 1.0x |
| 1.3x |
| 1.8x |
| 1.5x |
| 1.3x |
| EPS | $0.28 | -$6.50 | -$0.60 | $1.37 | $1.92 | $0.20 | $1.60 |
| Profit margin | 1.73% | 1.73% | -44.56% | -3.90% | 9.46% | 13.57% | 1.73% | 9.52% |
| ROE | 1.51% | 1.51% | -38.12% | -2.40% | 5.78% | 8.39% | 0.90% | 6.15% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-10.6% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 32.9x |
| 2.7x |
| 0.00% |
| 8.77% |
| $3.7B |
| RLAYRelay Therapeutics, Inc. | $18.34 | — | 4.5x | 0.00% | -36.77% | $4.02B |
| ABCLAbCellera Biologics Inc. | $11.37 | — | 3.9x | 0.00% | -17.30% | $3.68B |
